Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se

Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative B

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst co

Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst cons

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization an

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical

Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutica

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photody

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical

Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photod

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst co

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, b

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Compa

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst co

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® i

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercia

Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending

Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the pri

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends paten

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.19) per share which beat the analyst cons

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst co

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up